“…Although the DFC formulation differs from the formulation proposed for marketing (i.e., ECT), the DFC formulation was administered both when ridaforolimus was given alone and in combination with ketoconazole to avoid a potential confounding effect of formulation. As with other rapamycin analogs, ridaforolimus exhibits saturable binding to erythrocytes that results in a relatively high blood to plasma ratio [3,14,15]. Given the relatively low ridaforolimus levels in plasma, the pharmacokinetic results in this evaluation are based on wholeblood, not plasma, exposures.…”